Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

[1]  J. Floege,et al.  Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  B. Molitoris,et al.  A Novel Method for Rapid Bedside Measurement of GFR. , 2018, Journal of the American Society of Nephrology : JASN.

[3]  E. Cholongitas,et al.  Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review , 2018, Annals of gastroenterology.

[4]  A. Advani,et al.  Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. , 2018, American journal of physiology. Renal physiology.

[5]  R. Lennon,et al.  Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how? , 2017, Pediatric Nephrology.

[6]  K. Dahan,et al.  Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[7]  G. Laverman,et al.  Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[8]  C. Fitzner,et al.  Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[9]  J. Klein,et al.  Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2017, Kidney international.

[10]  T. Cavero,et al.  Remission of Hematuria Improves Renal Survival in IgA Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[11]  F. Dekker,et al.  Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study. , 2017, Journal of the American Society of Hypertension : JASH.

[12]  M. Sims,et al.  Mini-Focus Issue: Special PopulationsClinical ResearchAldosterone, Renin, Cardiovascular Events, and All-Cause Mortality Among African Americans: The Jackson Heart Study , 2017 .

[13]  G. Remuzzi,et al.  Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[14]  Glen R Morrell,et al.  Magnetic Resonance Imaging of the Fibrotic Kidney. , 2017, Journal of the American Society of Nephrology : JASN.

[15]  David W. Johnson,et al.  Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial , 2017, JAMA.

[16]  J. Barratt,et al.  New insights into the pathogenesis of IgA nephropathy , 2017, Pediatric Nephrology.

[17]  C. Zeng,et al.  Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  F. Locatelli,et al.  Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial , 2017, The Lancet.

[19]  J. Lash,et al.  Association of Sleep Duration, Symptoms, and Disorders With Mortality in Adults With Chronic Kidney Disease , 2017, Kidney international reports.

[20]  F. Wang,et al.  MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[21]  M. Säemann,et al.  Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease , 2017, Annals of medicine.

[22]  Jai Radhakrishnan,et al.  A proposal for standardized grading of chronic changes in native kidney biopsy specimens. , 2017, Kidney international.

[23]  B. Rovin,et al.  A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. , 2017, Journal of the American Society of Nephrology : JASN.

[24]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[25]  D. Cattran,et al.  Membranous Nephropathy: Quantifying Remission Duration on Outcome. , 2017, Journal of the American Society of Nephrology : JASN.

[26]  J. Sayer.  Progress in Understanding the Genetics of Calcium-Containing Nephrolithiasis. , 2017, Journal of the American Society of Nephrology : JASN.

[27]  Jun Zhou,et al.  Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. , 2017, Autoimmunity reviews.

[28]  Su-xia Wang,et al.  A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[29]  K. Nath,et al.  A Proposal for a Serology-Based Approach to Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[30]  Merlin C. Thomas,et al.  Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. , 2016, Kidney international.

[31]  J. Lieske,et al.  The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. , 2016, Kidney international.

[32]  F. Hildebrandt,et al.  Genetic testing in steroid-resistant nephrotic syndrome: when and how? , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  J. Wetzels,et al.  Pharmacological treatment of primary membranous nephropathy in 2016 , 2016, Expert review of clinical pharmacology.

[34]  C. Tinelli,et al.  Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[35]  H. Kramer,et al.  Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  J. Fine,et al.  Patients with primary membranous nephropathy are at high risk of cardiovascular events. , 2016, Kidney international.

[37]  Krzysztof Kiryluk,et al.  Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese. , 2016, Journal of the American Society of Nephrology : JASN.

[38]  V. Jha,et al.  Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial , 2016, Nephrology.

[39]  U. Maggiore,et al.  Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). , 2016, Autoimmunity reviews.

[40]  F. Schena,et al.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. , 2015, The New England journal of medicine.

[41]  K. Shedden,et al.  Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker , 2015, Science Translational Medicine.

[42]  Chrysta C. Meadowbrooke,et al.  Glomerular Aging and Focal Global Glomerulosclerosis: A Podometric Perspective. , 2015, Journal of the American Society of Nephrology : JASN.

[43]  R. Camilla,et al.  Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy , 2015, Nephron.

[44]  D. Gipson,et al.  Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  Wenjing Zhang,et al.  Genetic polymorphisms in TNFSF13 and FDX1 are associated with IgA nephropathy in the Han Chinese population. , 2015, Human immunology.

[46]  Birgitte Bang Pedersen,et al.  Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? , 2015, Clinical kidney journal.

[47]  Yusuke Suzuki,et al.  Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  A. Thompson,et al.  Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[49]  G. Remuzzi,et al.  Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[50]  Huhai Zhang,et al.  Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis , 2015, Scientific Reports.

[51]  Sanjeev Sethi,et al.  Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  B. Julian,et al.  Current Understanding of the Role of Complement in IgA Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[53]  R. Coppo,et al.  Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. , 2015, Journal of the American Society of Nephrology : JASN.

[54]  J. Klein,et al.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. , 2014, The New England journal of medicine.

[55]  A. Cheung,et al.  GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[56]  W. Liu,et al.  The Diagnosis Accuracy of PLA2R-AB in the Diagnosis of Idiopathic Membranous Nephropathy: A Meta-Analysis , 2014, PloS one.

[57]  D. Karpman,et al.  Eculizumab treatment for rescue of renal function in IgA nephropathy , 2014, Pediatric Nephrology.

[58]  J. Wetzels,et al.  Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues. , 2014, Journal of the American Society of Nephrology : JASN.

[59]  S. Barbour,et al.  Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. , 2014, Kidney international.

[60]  Marina Sánchez,et al.  Association of C4d deposition with clinical outcomes in IgA nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[61]  S. Eiam‐Ong,et al.  The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial. , 2014, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[62]  M. Landray,et al.  Effects of lowering LDL cholesterol on progression of kidney disease. , 2014, Journal of the American Society of Nephrology : JASN.

[63]  L. Morando,et al.  Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments , 2014, Kidney international.

[64]  Yusuke Suzuki,et al.  A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[65]  A. Levin,et al.  Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. , 2013, Kidney international.

[66]  J. Wetzels,et al.  Treatment of idiopathic membranous nephropathy , 2013, Nature Reviews Nephrology.

[67]  V. D’Agati,et al.  The rise of renal pathology in nephrology: structure illuminates function. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[68]  E. Messias,et al.  Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies , 2013, Modern Pathology.

[69]  D. Adu,et al.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial , 2013, The Lancet.

[70]  M. Faouzi,et al.  Comparison of the glomerular filtration rate in children by the new revised Schwartz formula and a new generalized formula. , 2013, Kidney international.

[71]  A. Stefanović,et al.  Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease , 2013, Pediatric Nephrology.

[72]  Chrysta Lienczewski,et al.  Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multi-disciplinary approach , 2012, Kidney international.

[73]  R. Agarwal.  Resistant hypertension and the neglected antihypertensive: sodium restriction. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[74]  M. Goicoechea,et al.  Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. , 2012, Journal of the American Society of Nephrology : JASN.

[75]  J. Wetzels,et al.  Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[76]  B. Julian,et al.  Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[77]  P. Seo,et al.  Persistent or New Onset Microscopic Hematuria in Patients with Small Vessel Vasculitis in Remission: Findings on Renal Biopsy , 2012, The Journal of Rheumatology.

[78]  Zhuang Miao,et al.  Nonparametric ROC summary statistics for correlated diagnostic marker data , 2012, Statistics in medicine.

[79]  Jai Radhakrishnan,et al.  Notice , 2012, Kidney International Supplements.

[80]  Jonathan Barratt,et al.  An update on the pathogenesis and treatment of IgA nephropathy. , 2012, Kidney international.

[81]  M. Tonelli,et al.  Comparison of concurrent complications of CKD by 2 risk categorization systems. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[82]  O. Djurdjev,et al.  Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. , 2012, Kidney international.

[83]  K. McCoy,et al.  Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. , 2011, The Journal of clinical investigation.

[84]  David M. Beck,et al.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[85]  B. Julian,et al.  Validation of the Oxford classification of IgA nephropathy. , 2011, Kidney international.

[86]  John F. Bertram,et al.  Human nephron number: implications for health and disease , 2011, Pediatric Nephrology.

[87]  Loreto Gesualdo,et al.  Genome-wide association study identifies susceptibility loci for IgA nephropathy , 2011, Nature Genetics.

[88]  L. Kiemeney,et al.  Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. , 2011, The New England journal of medicine.

[89]  T. Wilt,et al.  Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[90]  Kirsten Bibbins-Domingo,et al.  Projected effect of dietary salt reductions on future cardiovascular disease. , 2010, The New England journal of medicine.

[91]  S. Tang,et al.  Long-term study of mycophenolate mofetil treatment in IgA nephropathy. , 2010, Kidney international.

[92]  L. Stevens,et al.  Measured GFR as a confirmatory test for estimated GFR. , 2009, Journal of the American Society of Nephrology : JASN.

[93]  G. Schwartz,et al.  Measurement and estimation of GFR in children and adolescents. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[94]  V. D’Agati,et al.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. , 2009, Kidney international.

[95]  Sandrine Florquin,et al.  The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. , 2009, Kidney international.

[96]  H. Nagaraja,et al.  Random Spot Urine Protein/Creatinine Ratio Is Unreliable for Estimating 24-Hour Proteinuria in Individual Systemic Lupus Erythematosus Nephritis Patients , 2009, Nephron Clinical Practice.

[97]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[98]  Yusuke Suzuki,et al.  Toll-like receptor 9 affects severity of IgA nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.

[99]  H. Beanlands,et al.  The impact of sex in primary glomerulonephritis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[100]  J. Scholey,et al.  Remission of proteinuria improves prognosis in IgA nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.

[101]  V. D’Agati,et al.  Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[102]  J. Wetzels,et al.  Serum creatinine is a poor marker of GFR in nephrotic syndrome. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[103]  B. Maes,et al.  Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. , 2004, Kidney international.

[104]  E. Morales,et al.  Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[105]  F. Lai,et al.  The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. , 2001, The American journal of medicine.

[106]  N. Nahman,et al.  Renoprotection: one or many therapies? , 2001, Kidney international.

[107]  K. Dahan,et al.  Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. , 2017, Journal of the American Society of Nephrology : JASN.

[108]  C. Fitzner,et al.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. , 2015, The New England journal of medicine.

[109]  R. Coppo,et al.  The MEST score provides earlier risk prediction in IgA nephropathy. , 2015, Kidney international.

[110]  Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. , 2015, Kidney international.

[111]  J. Hodgin,et al.  Defining nephrotic syndrome from an integrative genomics perspective , 2014, Pediatric Nephrology.

[112]  B. Kasiske,et al.  KDIGO Clinical Practice Guideline for Glomerulonephritis , 2012 .

[113]  G. Beck,et al.  Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. , 2011, Clinical journal of the American Society of Nephrology : CJASN.